Effects of a dual LN-type calcium channel blocker cilnidipine on blood pressure, pulse rate, and autonomic functions in patients with mild to moderate hypertension

Clinical and Experimental Hypertension

Volumn 31, Issue 7, 2009, Pages 595-604

  Kai, Tatsuya ^a   Kuzumoto, Yoshimasa ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Autonomic function; Cilnidipine; Hypertension; Pulse rate; Valsalva maneuver

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BIGUANIDE DERIVATIVE; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL N TYPE; CILNIDIPINE; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; HEART BEAT; HUMAN; HYPERPNEA; HYPERTENSION; MALE; MONOTHERAPY; ORTHOSTATIC BLOOD PRESSURE; PULSE RATE; SYSTOLIC BLOOD PRESSURE; TILT TABLE TEST; TREATMENT DURATION; VALSALVA MANEUVER; BLOOD PRESSURE; CLINICAL TRIAL; DIASTOLE; HEART RATE; MIDDLE AGED; PATHOPHYSIOLOGY; SYSTOLE;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIASTOLE; DIHYDROPYRIDINES; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; SYSTOLE; TILT-TABLE TEST; VALSALVA MANEUVER;

EID: 70449396067     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641960902929453     Document Type: Article

References (27)

1. Godfraind T. Calcium antagonists and vasodilatation. Pharmacol Ther 1994;64:37-75.
2. Staessen JA, Thijs L, Fagard RH, Birkenhäger WH, Arabidze G, Babeanu S, Gil-Extremera B, Bulpitt CJ, Davidson C, de Leeuw PW, Efstratopoulos AD, Fletcher AE, Fogari R, Jääskivi M, Kawecka-Jaszcz K, Nachev C, Petrie JC, Seux ML, Tuomilehto J, Webster J, Yodfat Y. Calcium channel blockade and cardiovascular prognosis in the European trial on isolated systolic hypertension. Hypertension 1998;32:410-416.
3. Muth JN, Bodi I, Lewis W, Varadi G, Schwartz A. A Ca2+-dependent transgenic model of cardiac hypertrophy: A role for protein kinese C alpha. Circulation 2001;103:140-147.
4. Gillman MW, Kannel WB, Belanger A, D'Aqostino RB. Influence of heart rate on motality among persons with hypertension: The Framingham Study. Am Heart J 1993;125: 1148-1154.
5. Sugiyama A, Takahara A, Ando K, Nakamura Y, Hashimoto K. Comparison of the direct negative dromotrophic effect of a new calcium channel blocker, cilnidipine, with that of nicardipine. Heart Vessels 2005;20:112-115.
6. Yoshimoto R, Dohmoto H, Yamada K, Goto A. Prolonged inhibition of vascular contraction and calcium influx by the novel 1,4-dihydropyridine calcium antagonist cinaldipine (FRC-8653). Jpn J Pharmacol 1991;56:225-229.
7. Nagai H, Minatoguchi S, Chen XH, Wang N, Arai M, Uno Y, Lu C, Misao Y, Onogi H, Kobayashi H, Takemura G, Maruyama R, Fujiwara T, Fujiwara H. Cilnidipine, an N+L-type dihydropyridine Ca channel blocker, suppresses the occurrence of ischemia/reperfusion arrhythmia in a rabbit model of myocardial infarction. Hypertens Res 2005;28:361-368.
8. Fujii S, Kameyama K, Hosono M, Hayashi Y, Kitamura K. Effect of cilnidipine, a novel dihydropyridine Ca++-channel antagonist, on N-type Ca++ channel in rat dorsal root ganglion neurons. J Pharmacol Exp Ther 1997;280:1184-1191.
9. Uneyama H, Takahara A, Dohmoto H, Yoshimoto R, Inoue K, Akaike N. Blockade of N-type Ca2+ current by cilnidipine (FRC-8653) in acutely dissociated rat sympathetic neurons. Br J Pharmacol 1997;122:37-42.
10. Uneyama H, Uchida H, Yoshimoto R, Ueno S, Inoue K, Akaike N. Effects of a novel antihypertensive drug, cilnidipine, on catecholamine secretion from differentiated PC12 cells. Hypertension 1998;31:1195-1199.
11. Minami J, Ishimitsu T, Kawano Y, Numabe A, Matsuoka H. Comparison of 24-hour blood pressure, heart rate, and autonomic nerve activity in hypertensive patients treated with cilnidipine or nifedipine retard. J Cardiovasc Pharmacol 1998;32:331-336. (Pubitemid 28350656)
12. Minami J, Ishimitsu T, Higashi T, Numabe A, Matsuoka H. Comparison between cilnidipine and nisoldipine with respect to effects on blood pressure and heart rate in hypertensive patients. Hypertens Res 1998;21:215-219.
13. Sakata K, Shirotani M, Yoshida H, Nawada R, Obayashi K, Togi K, Miho N. Effects of amlodipine and cilnidipine on cardiac sympathetic nerve systems and neurohurmonal status in essential hypertension. Hypertension 1999;33:1447-1452.
14. Kihara M, Takahashi M, Nishimoto K, Okuda K, Matsui T, Yamakawa T, Okumura A. Autonomic dysfunction in elderly bedfast patients. Age Ageing 1998;27:551-555.
15. American Autonomic Society. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Clin Auton Res 1996;6:125-126.
16. Benarroch EE, Opfer-Gehrking TL, Low PA. Use of photoplethysmographic technique to analyze the Valsalva maneuver in normal man. Muscle Nerve 1991;14:1165-1172.
17. Sandroni P, Benarroch EE, Low PA. Pharmacological dissection of components of Valsalva maneuver in adrenergic failure. Appl Physiol 1991;71:1563-1567.
18. Low PA. Autonomic nervous system function. J Clin Neurophysiol 1993;10:14-27.
19. Levy MN. Sympathetic-parasympathetic interaction in the heart. Circ Res 1971;29:437-445.
20. Sunagawa K, Kawada T, Nakahara T. Dynamic nonlinear vago-sympathetic interaction in regulating heart rate. Heart Vessels 1998;13:157-174.
21. Kawada T, Ikeda Y, Sugimachi M, Shishido T, Kawaguchi O, Yamazaki T, Alexander J, Sunagawa K. Bidirectional augmentation of heart rate regulation by autonomic nervous system in rabbits. Am J Physiol 1996;271:H288-H295.
22. Kato K, Wakamori M, Mori Y, Imoto K, Kitamura K. Inhibitory effects of cilnidipine on peripheral and brain N-type Ca2+ channels expressed in BHK cells. Neuropharmacology 2002;42:1099-1108.
23. Hoshide S, Kario K, Ishikawa J, Eguchi K, Shimada K. Comparison of the effects of cilnidipine and amlodipine on ambulatory blood pressure. Hypertens Res 2005;28:1003-1008.
24. Yamagishi T. Beneficial effect of cilnidipine on morning hypertension and white-coat effect in patients with essential hypertension. Hypertens Res 2006;29:339-344.
25. Morimoto S, Takeda K, Oguni A, Kido H, Harada S, Moriguchi J, Itoh H, Nakata T, Sasaki S, Nakagawa M. Reduction of white coat effect by cilnidipine in essential hypertension. Am J Hypertens 2001;14:1053-1057.
26. Uchida R, Yamazaki J, Ozeki S, Kitamura K. State-dependent inhibition of L-type Ca2+ channels in A7r5 cells by cilnidipine and its derivatives. Jpn J Pharmacol 2001;85:260-270.
27. Nagahama S, Norimatsu T, Maki T, Yasuda M, Tanaka S. The effect of combination therapy with an L/N-type Ca2+ channel blocker, cilnidipine, and an angiotensin II receptor blocker on the blood pressure and heart rate in Japanese hypertensive patients: An observational study conducted in Japan. Hypertens Res 2007;30:815-822.